Cargando…

A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus

The optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is still a debatable point; however, randomized trials for strategies including neoadjuvant or adjuvant chemotherapy (CT), radiotherapy, or chemoradiotherapy (CRT) are not always available. This network meta-analysis aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yunpeng, Wang, Yongqiang, Shan, Lei, Peng, Chuanliang, Zhang, Wenhao, Zhao, Xiaogang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990939/ https://www.ncbi.nlm.nih.gov/pubmed/33762694 http://dx.doi.org/10.1038/s41598-021-86102-8

Ejemplares similares

Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials
por: Kumar, Tarun, et al.
Publicado: (2020)

Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus
por: Heise, Joachim W, et al.
Publicado: (2001)

Adjuvant Chemotherapy for Pathological Node-Positive Disease in Squamous Cell Carcinoma of the Esophagus after Neoadjuvant Chemoradiotherapy Plus Surgery
por: Lin, Jing-Wei, et al.
Publicado: (2022)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

Radically resected node-negative squamous cell carcinoma of thoracic esophagus: recurrence pattern and indication for adjuvant therapy
por: Fang, W, et al.
Publicado: (2013)

Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
por: Crook, Christiana J., et al.
Publicado: (2023)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Learning curve for minimally invasive oesophagectomy of oesophageal cancer and survival analysis
por: Zhao, Yunpeng, et al.
Publicado: (2021)

MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2018)

Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease
por: Ishikura, Satoshi, et al.
Publicado: (2020)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Correction to: MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2018)

Systemic treatments for resectable carcinoma of the esophagus
por: Leowattana, Wattana, et al.
Publicado: (2023)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
por: van Heijl, M, et al.
Publicado: (2008)

Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
por: Nakanoko, Tomonori, et al.
Publicado: (2013)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials
por: Zhao, Xin, et al.
Publicado: (2018)

Beyond Squamous Cell Carcinoma: Basaloid Squamous Cell Carcinoma of the Esophagus
por: Song, Heeyah, et al.
Publicado: (2021)

Squamous Cell Carcinoma and Neuroendocrine Carcinoma Colliding in the Esophagus
por: Dias, André Roncon, et al.
Publicado: (2010)

Trimodal therapy in squamous cell carcinoma of the esophagus
por: Matuschek, C, et al.
Publicado: (2011)

Synchronous triple squamous cell carcinoma of the esophagus
por: Petroianu, Andy, et al.
Publicado: (2018)

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
por: Malthaner, Richard A, et al.
Publicado: (2004)

Erratum to: Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
por: Nakanoko, Tomonori, et al.
Publicado: (2013)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Isolation of circulating tumor cells in patients undergoing surgery for esophageal cancer and a specific confirmation method
por: Zhao, Yunpeng, et al.
Publicado: (2019)

Isolation of circulating tumor cells in patients undergoing surgery for esophageal cancer and a specific confirmation method
por: Zhao, Yunpeng, et al.
Publicado: (2019)

Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Yap, Wing-Keen, et al.
Publicado: (2022)

Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis
por: Zhao, Xiao-han, et al.
Publicado: (2018)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy
por: Chao, Yin-Kai, et al.
Publicado: (2015)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Expression and Significance of TRIM 28 in Squamous Carcinoma of Esophagus
por: Liu, Bo, et al.
Publicado: (2018)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection
por: Ye, Yanyan, et al.
Publicado: (2023)

PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2018)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma
por: Chen, Zhencong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ri1b5qvkqnmt9f2l67978t6u0s